Project description
Innovative ICT platform for diabetes self-management
Diabetes is a fast-growing disease impacting a significant portion of the European population, leading to death, amputation, blindness, and renal failure. It poses a significant societal and economic burden. The EU-funded ProEmpower project aims to obtain an integrated ICT solution for disease self-management. Through 10 action areas, it seeks to achieve optimal health outcomes. The project’s innovative and interoperable platform will provide secure access to necessary devices and health records, enabling early detection, personalised decision support, self-management, and peer support. By implementing the chronic care model, the project aims to address the specific needs of type 2 diabetes at all stages, empowering individuals through personalised guidelines and efficient use of clinical data.
Objective
Public procurers in ProEmpower aim to procure a disease self-management solution to help meet the imminent threat of a diabetes epidemic. ProEmpower will make person-centred care reality - giving the patient the steering wheel - for optimal health outcomes. Very significant synergies will be reaped by supporting all 10 action areas of diabetes management in an integrated ICT solution. Early detection, personal decision support, self management and peer support are to be delivered from a platform with full interoperable and secure access to the necessary devices and health records. ProEmpower will apply the internationally acclaimed Chronic Care Model to specify support needs for type 2 diabetes at all stages. Self-management and treatment will be supported by personalised guidelines and making the best use of clinical data. In this way a quality culture in healthcare will be fostered and learning healthcare systems made reality.
Suppliers will be rigorously evaluated after each of the four procurement phases, comprising (I) an open market consultation supported by the European eHealth Competition, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 200 patients and 40 professionals.
Fully rolled out in the four countries, enabled by procurers with the authority and capacity in their countries and regions, ProEmpower will serve 12 million diabetes patients.
Reductions in diabetes-related death, amputation, blindness and renal failure promise cost relief of € 53 billion over 7 years in the four countries. Suppliers can expect a turnover of € 5 billion a year. Proven ability to cover the four different health systems promises ProEmpower suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.
Fields of science
Programme(s)
Funding Scheme
PCP - Pre-Commercial ProcurementCoordinator
06434 Ankara
Türkiye